UPPSALA, Sweden, Dec. 13 /CNW/ - Phadia today announced that it has
entered into an agreement to acquire 100 per cent of the shares in the
Chinese marketing company WKL from the parent company MeiRui. The
acquisition is made through AllergonAB, a wholly owned subsidiary of
Phadia, and is subject to approval by Chinese authorities.
Nanjing-based WKL has successfully been marketing and distributing
Phadia products including ImmunoCAP in China for 10 years. WKL has over
50 employees and more than 100 hospital customers in China's major
The Chinese operations are among the fastest growing areas within
Phadia. The prevalence of allergy is increasing and 30 percent of all
children are expected to develop some form of allergy in the future.
"The acquisition is strategically important for Phadia. It will further
improve diagnosis and management of allergies and provide a strong
platform for accelerated growth," says Jean Forcione, Chief Operating
Completion of the transaction is expected by the end of 2010, and is
subject to regulatory approval.
PhadiaAB is a global leader in allergy, asthma and autoimmunity
diagnostics. Phadia develops, manufactures and markets complete blood
test systems to support clinical diagnosis and management. Phadia has
marketing companies in more than 20 countries and distributors in about
Phadia is owned by the leading European buyout firm Cinven. For more
information please visit http://www.phadia.com
For further information: For further information:
VP Marketing, Corporate Communication, Scientific Affairs